The purpose of this study is to find out if the study drug, Anifrolumab, is effective and safe for pediatric participants with moderate to severe active systemic lupus erythematosus (SLE) while on background standard of care therapy. Researchers will also be testing how the body processes a drug by measuring how quickly the drug is absorbed by the body, how quickly it is broken down by the body, and how long it remains in the body (pharmacokinetics). Subjects will be asked to come into the Rheumatology clinic for blood, hepatitis/HIV, urine, and pregnancy testing, physical exam, an electrocardiogram (ECG), questionnaire completion, medical record review, corticosteroid use, and administration of study drug. Anifrolumab is administered as an infusion every 4 weeks over the course of the study.

The purpose of this study is to find out if the study drug, MAS825, is effective in preventing flares and safe for children with NLRC4-Gain of Function (GOF). Researchers will also be testing how the body processes a drug by measuring how quickly the drug is absorbed by the body, how quickly it is broken down by the body, and how long it remains in the body (pharmacokinetics). Subjects will be asked to come into the Rheumatology clinic for blood and stool testing, physical exam, an electrocardiogram (ECG), questionnaire completion, and administration of study drug. Participation will last for up to 4 years.

The purpose of this study is to find out if the study drug, Obinutuzumab, is effective in achieving a complete renal response for adolescents with active class III or IV lupus nephritis. Researchers will also be testing how the body processes a drug by measuring how quickly the drug is absorbed by the body, how quickly it is broken down by the body, and how long it remains in the body (pharmacokinetics). Subjects will be asked to come into the Rheumatology clinic for blood, hepatitis and pregnancy testing, physical exam, an electrocardiogram (ECG), questionnaire completion, chest x-ray, MMF/oral corticosteroid use, medical record review, optional genetic testing, and administration of study drug. Obinutuzumab is administered as an infusion 5 times over the course of the study.

This is a clinical trial to study the use of Tadekinig alfa or placebo (medication) in the treatment of NLRC4 MAS mutation or XIAP deficiency. This study involves taking the medication every 48 hours for up to 26 weeks. Participants will also be required to attend up to 14 in-person study visits to review their disease state while they are taking the medication. Compensation for time and travel related to study visits may be provided to qualified participants.

This is a study to measure the effectiveness of the medication Voclosporin compared to placebo in adolescent patients with active lupus nephritis. Volcosporin is an outpatient, oral medication.